Theranostic Application of FAPI in Advanced Laryngeal Squamous Cell Carcinoma: 99m Tc-FAPI-46 SPECT/CT Guided 177 Lu-FAPI-2286 Therapy.

Clin Nucl MedMay 15, 2026 (epub)
Case ReportOncology (Medical)Radiology (Diagnostic)

Haniye Elahifard, Mohammad Hadi Samadi, Mohsen Saberifar et al.

✦ AI-curated · Sources linked

Case in brief

A 47-year-old man with advanced laryngeal squamous cell carcinoma developed widespread skeletal metastases after chemotherapy. 99m Tc-FAPI-46 SPECT/CT imaging revealed significant FAPI uptake in the primary tumor and metastases, accurately depicting the disease burden. He was treated with 177 Lu-FAPI-2286 radioligand therapy for palliative care, with post-treatment imaging showing tracer accumulation in all known disease sites.

Diagnostic / clinical pearl

FAPI-based imaging can effectively reflect disease burden in advanced laryngeal squamous cell carcinoma and guide targeted radioligand therapy.

Why it matters

This case underscores the potential of theranostic applications of FAPI in managing advanced cancers, particularly in assessing treatment response and disease progression.

Source

PubMed · PMID 42149939

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.